NRS

LAURA GELLER BEAUTY FOUNDATION CELEBRATES 20 YEARS WITH NEW ACCOLADES AND CAMPAIGN

Retrieved on: 
Wednesday, January 31, 2024

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Laura Geller Beauty, a pioneer in the makeup industry and known for artisan-crafted baked makeup, specifically formulated for mature skin, is celebrating its 20th-anniversary of its best-selling and cult-favorite product, Baked Balance-n-Brighten Color Correcting Foundation.

Key Points: 
  • NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Laura Geller Beauty, a pioneer in the makeup industry and known for artisan-crafted baked makeup, specifically formulated for mature skin, is celebrating its 20th-anniversary of its best-selling and cult-favorite product, Baked Balance-n-Brighten Color Correcting Foundation.
  • To mark this significant milestone, Laura Geller Beauty has launched the 'Let's Face It' campaign with a series of content to be leveraged across brand social channels and digital platforms.
  • "'Let's Face It' is an acknowledgment that we must change our beauty routines as we age," says Geller.
  • Laura Geller Beauty's products, including the best-selling Baked Balance-n-Brighten Color Correcting Foundation, are available on QVC, LauraGeller.com, Amazon, and other select retailers.

Blackbird.AI Launches Automated Narrative Feed Module Powered By The RAV3N Risk LLM To Combat The #1 Global Risk - Misinformation and Disinformation

Retrieved on: 
Wednesday, January 24, 2024

NEW YORK, Jan. 24, 2024 /PRNewswire/ -- Blackbird.AI, the global leader in protecting organizations from narrative attacks created by misinformation and disinformation, has unveiled an innovative AI-based offering to its product lineup: the automated Narrative Feed module powered by the RAV3N Risk LLM as an integral part of its narrative intelligence platform, Constellation. This announcement marks a significant advancement in the battle against narrative attacks, which the World Economic Forum (WEF) has identified as the world's foremost global risk in its Global Risks Report 2024.

Key Points: 
  • NEW YORK, Jan. 24, 2024 /PRNewswire/ -- Blackbird.AI, the global leader in protecting organizations from narrative attacks created by misinformation and disinformation, has unveiled an innovative AI-based offering to its product lineup: the automated Narrative Feed module powered by the RAV3N Risk LLM as an integral part of its narrative intelligence platform, Constellation.
  • Enabling the Narrative Feed module significantly elevates customer capabilities to discover emergent, harmful narratives as they gain online momentum.
  • Integrating Narrative Feed and our proprietary RAV3N Risk LLM into our Constellation Platform is an evolution in narrative risk protection for organizations worldwide."
  • The world-class RAV3N Narrative Intelligence and Research Team works deeply with customers to identify narrative attacks and risks that impact them.

ILUS Acquires the Majority Stake of Samsara Luggage, Inc.

Retrieved on: 
Wednesday, January 10, 2024

The company confirms that is has acquired the controlling interest in the SEC Reporting OTC listed company, Samsara Luggage, Inc. (OTC: SAML).

Key Points: 
  • The company confirms that is has acquired the controlling interest in the SEC Reporting OTC listed company, Samsara Luggage, Inc. (OTC: SAML).
  • On January 3, 2024, ILUS acquired a convertible note from YAII PN, LTD with outstanding principal and accrued interest of $600,684.93.
  • On January 5, 2024, ILUS converted the note into 150,753,425 shares of common stock in SAML pursuant to the terms of the exchange note which was filed in ILUS’ Schedule 13D.
  • As a result of the conversion, as of January 5, 2024, ILUS acquired control of 91.5% of the outstanding shares in SAML.

NRSInsights’ December 2023 Retail Same-Store Sales Report

Retrieved on: 
Monday, January 8, 2024

NEWARK, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- NRSInsights, a provider of sales data and analytics drawn from retail transactions processed through the National Retail Solutions (NRS) point-of-sale (POS) platform, today announced comparative same-store sales results for December 2023 and the three months then ended.

Key Points: 
  • NEWARK, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- NRSInsights , a provider of sales data and analytics drawn from retail transactions processed through the National Retail Solutions (NRS) point-of-sale (POS) platform, today announced comparative same-store sales results for December 2023 and the three months then ended.
  • For the three months ended December 31, 2023, same-store sales increased 3.4% compared to the same three months in 2022.
  • The NRSInsights monthly Same-Store Retail Sales Reports are intended to provide timely topline data reflective of sales at NRS’ network of independent, predominantly urban, retail stores.
  • Same-store data comparisons of December 2023 with November 2023 are derived from approximately 209 million transactions processed through 23,443 stores.

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

Retrieved on: 
Tuesday, December 5, 2023

MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated to Complete Patient Recruitment during Q1 2024

Key Points: 
  • "We are delighted to have the world-renowned Massachusetts General Hospital contributing to our MAvERIC-Pilot study enrollment," commented Dr. Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development.
  • "Mass General has been consistently ranked as a top hospital in the United States and has the largest hospital-based research program in the country.
  • We look forward to the support of Mass General's clinicians and participating patients towards reaching full enrollment in this ground-breaking study."
  • MAvERIC-Pilot is enrolling 25 patients at eight prominent medical research centers in the United States that specialize in pericarditis care.

Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia

Retrieved on: 
Wednesday, December 20, 2023

CHATHAM, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Phase 3 RESILIENT study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) met its pre-specified primary endpoint in the second of two positive Phase 3 clinical trials, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia (Table 1). Statistically significant and clinically meaningful results were also seen in all key secondary endpoints related to improving sleep quality, reducing fatigue, and improving overall fibromyalgia symptoms and function. Additionally, as it relates to improving daily pain, treatment with TNX-102 SL showed a robust and clinically meaningful analgesic effect size of 0.38, with rapid onset of action, separating from placebo for each week of the study. TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies, and no new safety signals were observed. Tonix plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024 for TNX-102 SL for the management of fibromyalgia. An estimated 6 million to 12 million U.S. adults are living with fibromyalgia, the majority of whom are women.

Key Points: 
  • TNX-102 SL is a non-opioid, centrally-acting analgesic, the active ingredient of which has a known, favorable safety profile from decades of use.
  • “The sublingual formulation of TNX-102 SL, which uses our proprietary Protectic® and Angstro® technologies, is integral to our treatment paradigm.
  • Consistent with the proposed mechanism that TNX-102 SL acts in fibromyalgia through improving sleep quality, TNX-102 SL showed statistically significant improvement of sleep by two main measures.
  • Adverse events resulted in premature study discontinuation in 6.1% of those who received TNX-102 SL compared with 3.5% of placebo recipients.

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

Retrieved on: 
Monday, December 18, 2023

STAMFORD, Conn., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KIND 1 study evaluating the efficacy and safety of oral difelikefalin as adjunct therapy to topical corticosteroids (TCS) for moderate-to-severe pruritus in adult patients with atopic dermatitis (AD). Oral difelikefalin as adjunct to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone, resulting in the Company’s decision to discontinue its clinical program in pruritus associated with atopic dermatitis.

Key Points: 
  • Oral difelikefalin as adjunct to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone, resulting in the Company’s decision to discontinue its clinical program in pruritus associated with atopic dermatitis.
  • “We are disappointed with the outcome of this study recognizing that comparing the adjunctive use of oral difelikefalin with TCS to TCS alone represented a high clinical bar based on anticipated real-world commercial use.
  • Oral difelikefalin as adjunct therapy to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone.
  • Oral difelikefalin was generally well tolerated with a safety profile similar to prior trials.

NRSInsights’ November 2023 Retail Same-Store Sales Report

Retrieved on: 
Friday, December 8, 2023

NEWARK, N.J., Dec. 08, 2023 (GLOBE NEWSWIRE) -- NRSInsights, a provider of sales data and analytics drawn from retail transactions processed through the National Retail Solutions (NRS) point-of-sale (POS) platform, today announced comparative same-store sales results for November 2023.

Key Points: 
  • NEWARK, N.J., Dec. 08, 2023 (GLOBE NEWSWIRE) -- NRSInsights , a provider of sales data and analytics drawn from retail transactions processed through the National Retail Solutions (NRS) point-of-sale (POS) platform, today announced comparative same-store sales results for November 2023.
  • For the three months ended November 30, 2023, same-store sales increased 3.7% compared to the same three months in 2022.
  • The average number of transactions per calendar day in November 2023 decreased 3.9% compared to October 2023.
  • The NRSInsights monthly Same-Store Retail Sales Reports are intended to provide timely topline data reflective of sales at NRS’ network of independent, predominantly urban, retail stores.

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Retrieved on: 
Monday, November 27, 2023

The Phase 1a portion of the trial was a standard single and multiple dose-escalation study in 72 healthy volunteers.

Key Points: 
  • The Phase 1a portion of the trial was a standard single and multiple dose-escalation study in 72 healthy volunteers.
  • The Phase 1b portion of the trial was a randomized, double-blind, placebo-controlled study examining zelnecirnon as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).
  • “We are pleased to have these exciting data published in the prestigious, peer-reviewed journal Allergy,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics.
  • Based on the efficacy and safety data observed in the Phase 1b study, RAPT initiated a dose-ranging Phase 2b study in patients with moderate-to-severe AD and a Phase 2a study in asthma.

NRS CORPORATION: Establishment of a New Logistics Site in Arizona, U.S.A.

Retrieved on: 
Friday, December 22, 2023

NRS CORPORATION is pleased to announce the opening of a new comprehensive logistics site in the U.S. state of Arizona, which has grown to become a center for the semiconductor and battery industry.

Key Points: 
  • NRS CORPORATION is pleased to announce the opening of a new comprehensive logistics site in the U.S. state of Arizona, which has grown to become a center for the semiconductor and battery industry.
  • This strategic move aims to meet the strong demand for chemical logistics in the U.S.
  • The facility is equipped with gas pads and storage for hazard classes for flammable, corrosive chemicals used in semiconductor and battery manufacturing.
  • NRS GROUP will continue to pursue the optimization of our customers' supply chains by providing comprehensive one-stop logistics services covering transportation, storage & distribution, and ISO tank container leasing.